世界のN-アセチルグルタミン酸合成酵素欠損症市場 – 2030年までの業界動向と予測

N-アセチルグルタミン酸合成酵素欠損症の市場分析と規模

N-アセチルグルタミン酸合成酵素欠損症は、出生児 30,000 人に 1 人の割合で起こる、まれな欠損症の一種です。この欠損症は、女性と男性に等しく影響します。この欠損症は認識されないことが多く、これらの障害は診断が不十分であるため、人口全体における尿素サイクル障害の頻度を把握することが困難です。神経症状は生命を脅かす可能性があり、発作、昏迷、昏睡などが含まれます。  

データブリッジ市場調査は、2023年から2030年の予測期間におけるN-アセチルグルタミン酸合成酵素欠損症市場の成長率を分析しています。予測期間中、N-アセチルグルタミン酸合成酵素欠損症市場の予想されるCAGRは、約3.50％になる傾向があります。市場は2022年に13億米ドルと評価され、2030年までに17億1000万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

N-アセチルグルタミン酸合成酵素欠損症市場の範囲とセグメンテーション

市場の定義

N-acetylglutamate synthetase (NAGS) deficiency is a rare type of genetic disorder that is typically characterized by complete or partial lack of the enzyme N-acetylglutamate synthetase. Excess ammonia travels to the CNS through the blood, leading to NAGS deficiency symptoms and physical findings. This synthetase is one of the six enzymes which play a major role in the breakdown and removal of nitrogen from the body. The lack of N-acetylglutamate synthetase (NAGS) enzyme causes excessive accumulation of nitrogen in the form of ammonia in the blood.  

N-Acetylglutamate Synthase Deficiency Market Dynamics

Drivers

• Increasing Treatment Developments

The treatment of NAGS deficiency aims to prevent excessive ammonia from formingaims to prevent excessive ammonia from forming or removing excessive ammonia during a hyperammonemic episode. Several long-term therapy for NAGS deficiency can be combined with dietary restrictions and the stimulation of alternate methods of converting and excreting nitrogen from the body. For instance, the U.S. FDA approved the use of Carbaglu (carbamylglutamate) tablets in 2010 to decrease blood ammonia levels in patients with NAGS deficiency. Carbaglu is manufactured by Orphan Europe. Some of the individuals who take carbamylglutamic acid may still need to follow certain dietary restrictions and may receive supplemental arginine. The initiation of carbaglu therapy has minimized the vulnerability of severe hyperammonemic episodes.

Opportunities

• Increasing Demand For Hospitals

Drug stores and hospitals are the major application segments of N-acetylglutamate synthase deficiency drugs. In 2015, the hospital segment dominated the global market with a share of more than 80% in revenue. The segment is estimated to witness major growth due to increasing healthcare expenditure and a growing number of patients suffering from life-threatening diseases

Restraints/Challenges

• Lack of Awareness

For many decades, this deficiency disease is not much known in several parts of the world. The appropriate treatment for the disease and its associated applications are unaware to the people. Thus, it hampers the market growth.   

• High Cost of Treatment Process

The enormous expenditure required for its treatment processes obstructs the market growth. Numerous market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.

This N-acetylglutamate synthase deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the N-acetylglutamate synthase deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global N-Acetylglutamate Synthase Deficiency Market Scope

The N-acetylglutamate synthase deficiency market is segmented on the basis of diagnosis, treatment, drug type, end-user distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Genetic Testing
• New-born Screening Others

Treatment

• Medications
• Alternative Treatment
• Others

Drug Type

• Branded
• Generic

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

N-Acetylglutamate Synthase Deficiency Market Regional Analysis/Insights

The N-acetylglutamate synthase deficiency market is analyzed and market size insights and trends are provided by diagnosis, treatment, drug type, end-user distribution channel as referenced above.

The major countries covered in the N-acetylglutamate synthase deficiency market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market ue to the presence of high healthcare expenditure and research & development.

Asia-Pacific is considered to grow over the coming years due to increased advancement in the technology as well as growing healthcare expenditure.

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更についても説明しています。また、国別データの予測分析を提供しながら、グローバルブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されています。 

競争環境と世界のN-アセチルグルタミン酸合成酵素欠損症市場シェア分析

N-アセチルグルタミン酸合成酵素欠損症市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータ ポイントは、N-アセチルグルタミン酸合成酵素欠損症市場に関連する会社の焦点にのみ関連しています。

N-アセチルグルタミン酸合成酵素欠損症市場で活動している主要企業は次のとおりです。

• レコルダティ希少疾患（イタリア）
• 国立小児病院（米国）
• マウントサイナイ・アイカーン医科大学（米国）
• ボストン小児病院（米国）

SKU-57480